Zevenbergen Capital Investments Has Decreased Its Holding in Celgene (CELG) by $15.96 Million as Share Price Declined; Intersect Ent (XENT) Shareholder First Light Asset Management Has Trimmed Position by $3.21 Million as Stock Value Rose

January 18, 2018 - By Adrian Mccoy

Zevenbergen Capital Investments Llc decreased its stake in Celgene Corporation (CELG) by 15.5% based on its latest 2017Q3 regulatory filing with the SEC. Zevenbergen Capital Investments Llc sold 110,053 shares as the company’s stock declined 3.49% while stock markets rallied. The institutional investor held 600,086 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $87.51M, down from 710,139 at the end of the previous reported quarter. Zevenbergen Capital Investments Llc who had been investing in Celgene Corporation for a number of months, seems to be less bullish one the $80.15 billion market cap company. The stock decreased 0.22% or $0.22 during the last trading session, reaching $101.8. About 4.48 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 18, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

First Light Asset Management Llc decreased its stake in Intersect Ent Inc (XENT) by 37.8% based on its latest 2017Q3 regulatory filing with the SEC. First Light Asset Management Llc sold 103,448 shares as the company’s stock rose 72.35% with the market. The institutional investor held 170,197 shares of the health care company at the end of 2017Q3, valued at $5.30 million, down from 273,645 at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Intersect Ent Inc for a number of months, seems to be less bullish one the $998.56M market cap company. The stock decreased 0.15% or $0.05 during the last trading session, reaching $33.9. About 55,780 shares traded. Intersect ENT, Inc. (NASDAQ:XENT) has risen 79.98% since January 18, 2017 and is uptrending. It has outperformed by 63.28% the S&P500.

Analysts await Intersect ENT, Inc. (NASDAQ:XENT) to report earnings on February, 27. They expect $-0.17 EPS, 0.00% or $0.00 from last year’s $-0.17 per share. After $-0.15 actual EPS reported by Intersect ENT, Inc. for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.

Among 9 analysts covering Intersect ENT (NASDAQ:XENT), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Intersect ENT had 20 analyst reports since August 17, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bank of America on Friday, December 18. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, December 6. Piper Jaffray maintained Intersect ENT, Inc. (NASDAQ:XENT) on Monday, August 21 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 2 by Deutsche Bank. The rating was downgraded by Northland Capital on Wednesday, May 31 to “Market Perform”. The company was maintained on Wednesday, September 13 by Canaccord Genuity. The rating was maintained by Piper Jaffray on Tuesday, September 29 with “Overweight”. The firm has “Overweight” rating given on Tuesday, January 2 by JP Morgan. On Thursday, October 6 the stock rating was initiated by Deutsche Bank with “Hold”. The stock of Intersect ENT, Inc. (NASDAQ:XENT) earned “Hold” rating by Northland Capital on Wednesday, August 2.

First Light Asset Management Llc, which manages about $154.73M and $315.80 million US Long portfolio, upped its stake in Atricure Inc (NASDAQ:ATRC) by 74,878 shares to 1.03M shares, valued at $23.13 million in 2017Q3, according to the filing. It also increased its holding in Codexis Inc (NASDAQ:CDXS) by 70,000 shares in the quarter, for a total of 344,990 shares, and has risen its stake in Entellus Medical Inc.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 earnings per share, up 24.11% or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38 billion for 14.54 P/E if the $1.75 EPS becomes a reality. After $1.78 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69% negative EPS growth.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. Credit Suisse maintained Celgene Corporation (NASDAQ:CELG) on Monday, October 30 with “Buy” rating. The firm has “Buy” rating by BMO Capital Markets given on Thursday, October 5. Jefferies initiated the stock with “Buy” rating in Monday, July 10 report. Stifel Nicolaus maintained it with “Buy” rating and $155.0 target in Thursday, September 7 report. The firm has “Buy” rating given on Friday, October 20 by SunTrust. As per Tuesday, August 22, the company rating was maintained by Cantor Fitzgerald. The rating was upgraded by Atlantic Securities to “Overweight” on Friday, December 8. The rating was downgraded by Wells Fargo on Thursday, October 26 to “Hold”. The rating was downgraded by Cantor Fitzgerald to “Neutral” on Friday, October 27. UBS maintained the stock with “Buy” rating in Friday, October 27 report.

Since August 2, 2017, it had 0 buys, and 5 insider sales for $6.27 million activity. Shares for $248,498 were sold by Curran Terrie on Monday, September 25. On Thursday, August 10 MARIO ERNEST sold $2.42 million worth of Celgene Corporation (NASDAQ:CELG) or 18,506 shares. $1.29M worth of Celgene Corporation (NASDAQ:CELG) was sold by CASEY MICHAEL D on Tuesday, September 5.

Zevenbergen Capital Investments Llc, which manages about $2.92 billion and $2.30B US Long portfolio, upped its stake in Wayfair Inc. (NYSE:W) by 389,420 shares to 461,190 shares, valued at $31.08 million in 2017Q3, according to the filing. It also increased its holding in Teladoc Inc. by 499,520 shares in the quarter, for a total of 1.32M shares, and has risen its stake in Constellation Brands Inc. (NYSE:STZ).

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It fall, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Scholtz And Ltd Com stated it has 3% of its portfolio in Celgene Corporation (NASDAQ:CELG). Artemis Invest Mgmt Limited Liability Partnership has 151,158 shares for 0.45% of their portfolio. Moreover, Tocqueville Asset Mngmt Limited Partnership has 0.39% invested in Celgene Corporation (NASDAQ:CELG) for 230,106 shares. State Of Alaska Department Of Revenue reported 4,285 shares. Qci Asset Mgmt Ny invested in 0% or 42 shares. Lateef Invest Limited Partnership holds 211,286 shares. Yorktown Management Co reported 2,100 shares. Wealthtrust holds 0.08% or 1,025 shares. Boys Arnold & Company Inc holds 22,060 shares. Thomas White International Ltd holds 7,977 shares or 0.2% of its portfolio. Signature & Inv Advsrs Lc has 128,883 shares. Alpine Woods Invsts Lc owns 8,500 shares. Rockefeller Fin Svcs has 0.06% invested in Celgene Corporation (NASDAQ:CELG). Andra Ap has 0.15% invested in Celgene Corporation (NASDAQ:CELG). Ngam Limited Partnership holds 0.38% or 247,311 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: